Q-omics provides the consensus-scored N4BP1 profile across patient tissues and cancer cell-line models. N4BP1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, N4BP1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, N4BP1 protein abundance shows 20,997 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, and HNSC as cancer lineages where N4BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for N4BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes N4BP1 survival associations across molecular data types. N4BP1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible N4BP1 RNA expression–survival associations across cancer types. High N4BP1 expression shows unfavorable associations in LIHC and ACC, but favorable associations in KIRC, SCLC, ESCA and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for N4BP1 RNA expression.
This table summarizes N4BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for N4BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. N4BP1 shows lower tumor expression in LUAD, THCA and LUSC and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher N4BP1 RNA expression in tumor versus normal tissue (log2 FC = +0.839, t-test p < 0.001).
This table shows molecular features associated with N4BP1 in patient tissues and cancer cell lines. In patient samples, N4BP1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, N4BP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
